San Diego, United States
Replicate Bioscience, Inc., founded in 2020, is at the forefront of RNA therapeutics, leveraging its novel self-replicating RNA (srRNA) technology. Under the slogan "The Power of RNA Amplified," the company is redefining the capabilities of RNA treatments by integrating two essential components into its off-the-shelf srRNAs: a virally derived genetic code for controlled amplification and RNA encoding therapeutic proteins.
This approach promises substantial improvements in applications such as oncology, infectious disease, and autoimmunity by offering enhanced protein expression and performance over traditional linear mRNA methods. The company's distinct advantage lies in its expert team and customizable srRNA vector library, reinforced by end-to-end development capabilities.
Headquartered in the United States, Replicate Bioscience has attracted significant investor interest, securing a $40.00M Series A investment from Apple Tree Partners in September 2021. As a biotechnology innovator, Replicate is positioned to play a pivotal role in expanding the reach and efficacy of RNA therapeutics.
